Shanghai Pharmaceuticals Holding Co Ltd Class A
601607: XSHG (CHN)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
¥14.78 | Vdrkm | Zrqrlhsz |
Shanghai Pharmaceuticals Reports Larger-Than-Expected Declines Due to COVID-19; FVE Unchanged
Narrow-moat Shanghai Pharmaceuticals, or SPH, announced quarterly earnings worse than our expectations. Although we revised our full-year revenue forecast this year downward by 4%, we think this is mostly due to the one-off impact from COVID-19 and our fair value estimate remains unchanged at HKD 20.30 per share.